This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.
Skip to main content Wednesday 25 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -WhitePapers -Event Market Access -News -Views (..)
billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.
This rapid processing not only enhances throughput, but will also allow pharmaceuticalcompanies to respond more swiftly to market demands. Can pharma tariffs “Make America Manufacture Again”?
Pharmaceutical sales in Brazil reached $17bn in 2021, according to GlobalData figures. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceuticalcompanies of international origin within the country. by 2040 based on statistics from OECD. </p> By Tanner Pharma Group.
Go deeper with GlobalData Reports Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzh. By GlobalData Learn more about Strategic Intelligence In light of the approvals of Leqembi and Kisunla, large pharmaceuticalcompanies are increasingly investing in Alzheimer’s disease through high-value acquisitions.
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -WhitePapers -Event Market Access -News -Views (..)
Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -WhitePapers -Event Market Access -News -Views (..)
billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal.
Not so China, and especially not so the lead five European countries – on average European pharmaceuticalcompanies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Biosimilars accelerate. Focus on customer engagement impact.
She has an extremely wide experience of international pharmaceutical industry issues, consulting to the world’s leading pharmaceuticalcompanies on global issues. She has been vice resident, European Marketing and Thought Leadership in IQVIA for 12 years. the impact of the pandemic on medicines markets and Rx launch.
Skip to main content Wednesday 18 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -WhitePapers -Event Market Access -News -Views (..)
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content